文献速递胸部技术与安全PETCT

基于[18F]FDG PET/CT代谢参数、炎症标志物及临床变量的新诊断NSCLC预后预测新分析方法

A novel analytical approach for outcome prediction in newly diagnosed NSCLC based on [18F]FDG PET/CT metabolic parameters, inflammatory markers, and clinical variables.
PubMed 文献 · Eur Radiol · 2022-10-12

回顾性纳入190例新诊断NSCLC患者,分为训练集127例和测试集63例,基于[18F]FDG PET/CT代谢参数、血清炎症标志物及临床变量构建预测PFS和OS的模型。联合模型(SULmax、MTV、NLR、ECOG PS)的C-index在训练集和测试集中均优于PET模型、临床模型及TNM分期,校准良好且决策曲线分析支持其临床实用性。

要点

  • 联合SULmax、MTV、NLR和ECOG PS的列线图可改善新诊断NSCLC的PFS和OS预测。
  • 联合模型预测效能优于TNM分期,有助于细化预后分层。
  • PET代谢参数联合炎症标志物和临床变量是可行的预后分析思路。

局限性

  • 回顾性研究设计。
  • 样本量有限(共190例)。
  • 单中心研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To develop a novel analytical approach based on 18F-fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) metabolic parameters, serum inflammatory markers, and clinical variables to improve the outcome prediction in NSCLC.

METHODS: A total of 190 newly diagnosed NSCLC patients who underwent pretreatment [18F]FDG PET/CT were retrospectively enrolled and divided into a training cohort (n = 127) and a test cohort (n = 63). Cox regression analysis was used to investigate the predictive values of PET metabolic parameters, inflammation markers, and clinical variables for progression-free survival (PFS) and overall survival (OS). Based on the results of multivariate analysis, PET-based, clinical, and combined models were constructed. The predictive performance of different models was evaluated using time-dependent ROC curve analysis, Harrell concordance index (C-index), calibration curve, and decision curve analysis.

RESULTS: The combined models incorporating SULmax, MTV, NLR, and ECOG PS demonstrated significant prognostic superiority over PET-based models, clinical models, and TNM stage in terms of both PFS (C-index: 0.813 vs. 0.786 vs. 0.776 vs. 0.678, respectively) and OS (C-index: 0.856 vs. 0.792 vs. 0.781 vs. 0.674, respectively) in the training cohort. Similar results were observed in the test cohort for PFS (C-index: 0.808 vs. 0.764 vs. 0.748 vs. 0.679, respectively) and OS (C-index: 0.836 vs. 0.785 vs. 0.726 vs. 0.660, respectively) prediction. The combined model calibrated well in two cohorts. Decision curve analysis supported the clinical utility of the combined model.

CONCLUSIONS: We reported a novel analytical approach combining PET metabolic information with inflammatory biomarker and clinical characteristics, which could significantly improve outcome prediction in newly diagnosed NSCLC.

KEY POINTS: • The nomogram incorporating SULmax, MTV, NLR, and ECOG PS outperformed the TNM stage for outcome prediction in patients with newly diagnosed NSCLC. • The established nomogram could provide refined prognostic stratification.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Zhang, Xu, Zhang, et al. A novel analytical approach for outcome prediction in newly diagnosed NSCLC based on [18F]FDG PET/CT metabolic parameters, inflammatory markers, and clinical variables. Eur Radiol. 2022. PMID: 36222865. doi:10.1007/s00330-022-09150-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。